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Abstract

Tissue engineering is an emerging field in medicine. The purpose is to synthesize new tissue that the body
will not reject but will use to heal the body from its own cells. It will lay down new material, with hopes
that the new tissue will develop and continue to regenerate. This is performed with the use of stem cells,
scaffolding and growth materials. Tissue engineering was birthed as a solution for organ transplants. The
technique for transplanting organs has a long history as it has evolved over the years and continues to
progress with technology. There have been many advantages to transplants, however, there are still many
complications. The future of tissue engineering is to completely eliminate any need for the transplant list
because researchers will be able to develop full organs from a person’s own cells that the body will not
reject. Plastic surgery, skin grafts, and potential development of organs are just some examples of the
areas in which tissue engineering has incredible benefits.
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Tissue Engineering and the Future of Organ Production from Stem Cells
Introduction
Medicine has been available since ancient times; however, the methods and procedures
doctors use to treat their patients have drastically changed from the early civilization times
(Guthrie et al., 2020). Modern technology has advanced medicine in ways that were not thought
possible. Through the development of technology over the years, the world has drastically
changed for the better. Now, with modern-day technology, doctors are able to more efficiently
and safely perform procedures such as heart transplants and brain surgery. An emerging trend in
transplant medicine is tissue engineering. It has rapidly gained momentum in medical research
due to the possibilities of healing and hope for patients. Tissue engineering has quickly become
the future for transplants, wound healing, and other forms of regenerative medicine through the
production of new tissue to heal the body from the inside out.
Organ Transplant
History of Organ Transplant
The process and discovery of organ transplant was a huge leap for the world of medicine.
Organ transplant can be dated back to the time of ancient Greece. There are several manuscripts
and Greek myths that involve the topic of transplanting, specifically relating to the body. Many
scholars speculate that organ transplant or preservation in ancient history was the original basis
for the current technique. Not only does it appear in Greek history, but many Roman and Chinese
myths from ancient manuscripts hold extravagant tales concerning the removal of organs
(Hamilton, 2012). These documents portray the transplant of organs in a deistic light because it
was considered a sacred task, and often only performed for their gods. The reason for these
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transplants stems back to the belief from these cultures that the preservation of a person’s body
after death, will allow them to have an exceptional experience in the afterlife. However, many of
these stories are just myths or wives’ tale and not true accounts of transplants. Nevertheless,
historians have found accounts which hold evidence of Native Americans performing skin grafts
in order to heal wounds, specifically burns.
During the 1600s, a man named Gasparo Tagliacozzi was one of the first plastic
surgeons, but he used skin from different areas of the person’s body to graft it into the
reconstruction of facial features (Frank & Frank, 1918). He discovered that the patient’s body
would accept their own skin best because samples from another donor often caused an immune
response which resulted in rejection of the transplanted skin (Frank & Frank, 1918). This was a
huge discovery which is now understood as transplant rejection. The idea of using organs from
other sources progressed to the point that in the early 1900s, doctors attempted to save several
patients with renal failure by transplanting organs from animals such as pigs or goats into the
patient’s body (Barker & Markmann, 2013). They had successfully performed dozens of organ
transplants between animals and decided to progress to humans. As one would imagine, the
transplants in humans were unsuccessful, but it continued to spark new ideas and inventions in
the minds of many aspiring medical pioneers and researchers.
In 1912, Alexis Carrell, a French surgeon, was awarded the Nobel Prize for discovering
techniques to successfully reconnect blood vessels, specifically in the context of organ transplant
surgeries (Barker & Markmann, 2013). Carell, with the help of a colleague, invented a machine
that was able to keep the organs that were taken outside of the body healthy and allow them to be
transplanted into another being (Barker & Markmann, 2013). Later on, this machine served as
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the building block for successfully being able to preserve organs for extended periods of time to
allow for the transportation of the organ to neighboring clinics or hospitals. The first successful
transplant occurred in the 1950’s in the United States with a team of surgeons. The patient had
severe kidney disease with no hope of surviving without a new kidney. A group of doctors from
a hospital in Boston were willing to try a transplant of a kidney from his twin brother. The
surgery was incredibly successful with no transplant rejection of the new kidney. At the time,
they were not completely aware that the reason for the success was due to the kidney being from
his twin brother (Barker & Markmann, 2013). Tissue transplant had been around for several
decades, but this was the first time that the patient’s body did not reject the organ or cause an
immune response (Barker & Markmann, 2013).
Following the success with the transplant of the twin brothers, many researchers were
beginning to understand that the rejection of the organs was more importantly correlated to a
person’s immune system attacking the new organ. With this understanding, medical
professionals started looking into ways to suppress the immune system for a time while the organ
was transplanted so it would not be rejected (Barker & Markmann, 2013). Immunosuppressive
therapies and medications were an emerging field at this time because there had not been a need
for them prior to transplants (Colaneri, 2014). An immunosuppressive drug called cyclosporine
was used with renal transplants and increased the success rate to roughly eighty percent
(Colaneri, 2014). This was a significant advancement for transplants as researchers were now
able to not only successfully perform the surgery but also see promising results with the patients.
The mortality rate decreased significantly for patients needing transplants and the next several
years consisted of an explosion of successful transplants moving from nonrenal organs to the

TISSUE ENGINEERING

7

liver, pancreas and even heart (Barker & Markmann, 2013). The continued development of
immunosuppressive therapies allowed surgeons to progress with organ transplants and see more
positive outcomes. With the help of new developments, organ transplant has been advanced and
altered with the emergence of new technology and discoveries every year.
Development of Modern-Day Organ Transplant
The process of organ transplant has been altered throughout the years, specifically with
immunosuppressive therapies and new techniques. When a patient who is near death has been
identified as a potential organ donor, the process begins with finding a match for their organs.
The process of matching organs begins by having a medical expert come and evaluate the patient
and the condition of their organs (Platt & Cascalho, 2013). Once this has been confirmed by the
coordinator and death has been declared by the medical staff, the family is then approached, and
the topic of organ donation is discussed. Upon obtaining consent from the family of the
deceased, the transplant coordinator matches up a recipient based on the location of the donor.
Upon choosing an available recipient closest to the hospital, with the most urgency, the
coordinator sends the information over to the transplant center to be evaluated. The final decision
of whether or not the donor is compatible for the recipient is left to the surgeon doing the
transplant. When approval is given from all participants, the process can begin to remove the
organs and preserve them until they are able to perform the surgery and transplant them into the
receiving patient. The organs are washed and preserved in sterile containers on ice where they
are transported to the site of the operation. The length of time each organ can be preserved
depends on the organ itself, with some being roughly twenty-four hours and others being only
four hours of preservation (Platt & Cascalho, 2013). This process of organ transplantation has
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been around for several decades and has proved to be successful with both the preservation of the
organs, as well as the procedure of transplanting them into the new patient. While organ
transplants give the patient a longer time of survival, they are not a permanent cure for the
patient because there is still a foreign organ in their body that will deteriorate over time (Rana &
Godfrey, 2019). Several organs, including kidneys, heart and pancreas, have an average lifespan
of ten years, while organs such as the liver have an average lifespan of about 5 years (Rana &
Godfrey, 2019). There are many different factors that can increase or decrease the length of time
that the organ can survive. In the end, the transplanted organ will not last as long as many people
would desire, but it increases the projected years of survival for the patient. Overall, organ
transplant is a blessing and gift that many are fortunate to receive.
Before the process described above was put in place, organ transplant was not as efficient
or effective. With the incredible success rate increasing and organ transplants becoming more
common and less perilous than they had been in the past, the U.S. Congress decided to put into
place the National Organ Transplant Act in 1984 (Gross, 2008). There was a scarcity of available
organs to be transplanted into patients that needed it, and they also had no methodology for
finding other patients that needed new organs. For example, if an organ was donated and
available for transplant, they only had a small radius of local hospitals and clinics that they were
able to use to find a recipient for the organ and if there was no one that qualified then the organ
would go to waste. Furthermore, the government sought to develop a system that efficiently and
accurately matched the patients with a correct donor (Gross, 2008). This method allowed organs
that were donated to be quickly paired with the necessary patient. At the time they were able to
keep organs alive and healthy for a time but waiting too long for a transplant resulted in the
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inability to use the donated organ for transplants. The National Organ Transplant Act also
prohibited and outlawed the sale of organs for monetary value in order to force all available
organs to be donated to save lives through the transplant system. This incredible organ act in
1984 allowed the process to be handled at a national level (Gross, 2008). The reason for this
stemmed from a desire to be fair and match the newly received organ with the person that needed
it the most, eliminating any bias involving all associated parties (Gross, 2008). It removed the
risk of having unfair protocols and maintained a professional, reliable and objective standpoint.
Over the years, the organ donation system has also improved with technology, specifically with
pairing the recipients with the donated organs. It began with using mail-in forms to track the
donors and recipients, but with improvements in technology, computers became available. With
the computers, they were able to create an electronic database that filed and managed the system
better and more efficiently than with paper. With so many patients needing new organs, the
organization decided they needed to create another system to place each individual on a list in
order of necessity and emergency. This led to the birth of the organ transplant list.
The organ transplant list is a system that was created by an organization in charge of
organ transplants in the United States called the United Network of Organ Sharing (UNOS)
(Singhal et al., 2009). This network has put together a list of all of the candidates and matches in
order to ensure equality and objective matching. The patients at the top of the waiting list are
individuals who have been waiting the longest time or are in the most critical need. When a new
organ becomes available, each individual on the recipient list is analyzed and compared with the
new organ to determine compatibility. They look at components including the genetics, size,
blood and tissue type of the organ; how long the patient has been on the waiting list; their need
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for a new organ; and the relative distance between the donor and the recipient (Singhal et al.,
2009). When the compatible recipients are identified, the patient closest to the location of the
donor often gets preference. The process then repeats as each new organ is donated and becomes
available for transplant.
Although the organ transplant list has been successful in ranking and pairing recipients
and donors, there is still a tremendous shortage of organs available for transplant. The recurring
issue is that the list of people needing organs is constantly growing in length, while the number
of available organs that are healthy and able to be used for transplants cannot keep up with the
excessive need (Satel et al., 2014). Almost 30 years after the introduction of the National Organ
Transplant Act, the wait time for organ recipients has increased by roughly five times, beginning
at almost a year wait to now 5 years before a new organ that is correctly matched becomes
available (Satel et al., 2014). Thousands of individuals have died over the years waiting for a
correct and available match. Despite the success stories of patients receiving new organs, there is
an almost equal number of individuals that did not survive due to the shortage of available
organs. With such a high percentage of mortality correlated to waiting for donated organs, the
goal for a long time has been to find a way to lower that number and ultimately eliminate the
problem through the use of technology.
The Influence of Technology on Organ Transplant
The innovation of science and research is directly connected with technology. As
technology emerges and progresses, so does the ability to advance and increase in other areas
such as science and medicine. Over the past decade, there has been an explosion of technology,
specifically regarding computers, phones and electronics. However, it has not stopped with
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electronics but has also spilled over into the world of medicine. With organ transplants
specifically, technology has allowed the transplant list to become more efficient and unbiased
due to transferring it to an online database. Even with all of the ways that technology has
increased and improved the process of organ transplantation, however, it cannot eliminate the
problem of the shortage of donated organs. The transplant system has evolved over the years and
been incredibly successful; however, it has not changed the lack of donors (Seetapun & Ross,
2017). Because of this problem, researchers have been searching and developing new techniques
that would eliminate the need for transplanting organs.
One of the emerging technologies is known as tissue engineering. Tissue engineering is a
relatively new field of study that is a mixture of engineering, science, and medicine (Howard et
al., 2008). It is often called regenerative medicine, where stem cells and other living materials
are engineered to form new tissue in the body. The entire purpose of engineering new tissue is to
use new manufactured cells in place of old tissue that has become damaged, whether from injury
or organ failure. In the late 1900s, researchers were able to create the dermis and epidermis of
the skin, which was an incredible breakthrough. They had predicted that in the next 15 to 20
years, tissue engineering would have progressed to the point of successfully reconstructing
organs; however, they were met by several challenges. The main hurdle they encountered was
that they needed to consider the vasculature and correct blood flow to the organs (Berthiaume et
al., 2011). The other main problem is that it is incredibly expensive to continue research, so it
had been funded by private donors in the past (Berthiaume et al., 2011). However, as research
has progressed, small organs have been produced and successfully used in transplants. This is a
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breakthrough, specifically with surgeries, because patients needing transplants will not be limited
to finding organ donors that match up correctly with their body (Satava, 2008).
Organ Transplants and Tissue Engineering
With the incredible breakthrough of this emerging area of research, a promising future
was seen for organ transplants. The reason for tissue engineering being an area of research for
transplants is because the future plan is to completely eliminate the transplant list and by doing
so, eliminate the problem of not having enough whole organs to be used (Seetapun & Ross,
2017). In order to understand how the transplant list can potentially be eliminated in the future,
one must understand the method by which they mean to replace it and how it works. Researchers
are looking to eliminate it by the production of new organs from the patient’s own cells which
will allow for the extension of their health. Medicine has allowed the lifespan of humans to
increase with time as new methods are discovered to prolong life. However, with this extension
comes other problems that need to be addressed like the need for new organs and the ability for
one’s body to accept these organs. Even with the advancement in immunosuppressive therapies
and medications in place used for organ transplants, they are still not a hundred percent reliable
and being on these medications takes a hard toll on the patient’s body over time. Doctors,
surgeons and researchers realized that they needed to find a way to synthesize full organs from
the person’s own cells so that the patient would not have the risk of their body rejecting the new
organ. There would also no longer be a need to take immunosuppressive medications because the
patient would be putting organs and tissues back in their body that had been made from their
own cells, so an immune response would not occur (Olson et al., 2011). The concept of tissue
engineering revolves around the regeneration of tissues and organs from cells (Olson et al.,
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2011). One of the key components is the location from which the cells are taken or the type of
tissue transplant.
There are several different sources for organ or tissue transplant (Sakaguchi et al., 2019).
These include autograft, allograft, xenograft and alloplast. First, autograft is a tissue graft where
the source of the tissue is the person’s own personal tissue or skin. Allograft is when the tissue is
from another human, whether alive or deceased as with cadavers. A Xenograft is tissue taken
from an altogether different species like an animal. Lastly, alloplast is when the tissue itself is
synthetically engineered or produced. Tissue engineering falls in the category of the last source
as it is synthetically made in the lab. Alloplasts are the most complicated and intricate of the four
styles of skin grafts because they are produced without any living element involved (Sakaguchi
et al., 2019). An example of an alloplast is the bioactive glasses that are integrated in with the
bone that mimics it and allows further growth and reconstruction of the bone. With the
foundation of the history and technique of organ transplants layed out, it is now important to get
a better understanding of what tissue engineering is and more specifically how it will tie in with
transplants.
Tissue Engineering
Tissue engineering stemmed from the idea of alloplasts (Sakaguchi et al., 2019). The
purpose is to use materials that connect the biomaterials and cells to heal the body on its own and
restore the function of tissues and organs (Sakaguchi et al., 2019). It falls under the category of
regenerative medicine, as discussed earlier, where the whole premise is that the body uses
outside components to heal itself through the reconstruction of new cells and tissues (Olson et
al., 2011).
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The body is made up of molecules and cells which make up the tissues, and tissues which
make up the organs. Next to atoms, the cells are the building blocks of the entire body. In order
to make new tissues and organs, the process must start with the building blocks, or cells
(Sakaguchi et al., 2019). The cells group together to create a structure often called the
extracellular matrix or referred to as scaffolding. The matrix and scaffolding are key to functions
of tissues and organs because they not only provide structure and support, but act as a network in
the signaling process (Howard et al., 2008). The signals that the cells are receiving in the matrix
control how the cell responds in the body. Researchers and engineers have been able to control
how the cells react by telling them to repair the damages from the inside (Howard et al., 2008).
Not only have they been able to manipulate the outcome and cause these cells to repair
themselves, but they have also been able to create new tissues by using these mechanisms
outside the body.
Tissue engineering has many uses including engineering new tissues or organs to replace
failing or faulty ones, as well as being used for testing of biocompatibility, specifically with
toxicity or pathogenicity (Sakaguchi et al., 2019). Currently, tissue engineering does not fall
under the category of patient treatment options. The reason for this is that it is still a new field
and there is a significant amount of research, trial, and testing to be done before it can be
implemented in human treatment (Satava, 2008). Small organs, such as arteries, bladders, a
trachea and even skin or cartilage has been used and implemented in humans. However, these
procedures are extremely expensive and at this point in time, still experimental (Satava, 2008).
Tissues of more complex organs have been produced in the lab through tissue engineering, but
these remain as experiments for further research since they are not functional or ready to be
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successfully placed inside a human (Satava, 2008). However, although these structures cannot be
fully used for their desired purpose, they are incredibly beneficial to research of drugs and
prescriptions. In the past, companies have tested their drugs on 2-D cell systems or cell assays in
an attempt to replicate the in vivo model of how a human body would respond to the drug (Nam
et al., 2015). Even though these experiments have been helpful to understand how the tissues
might respond, it is not as accurate as one would hope. The potential complication of this
situation is a huge concern because not being able to accurately replicate the environment of the
body and cell system in vivo means that these companies are not able to precisely predict the
response from the body in vivo (Nam et al., 2015). It is with some risk that these prescription
companies are producing their drugs when the accuracy of their preclinical tests is not adequate
(Nam et al., 2015). Studies have been done which demonstrate that 3-D models of these tissues
and cultures have a tremendous increase in accuracy when it comes to real life responses to the
medications (Nam et al., 2015). These tissue-engineered organs are useful for these cases in
research. Not only does it provide more accurate predictions, but because these tissues are
synthesized from the individual’s own cells, researchers can test medications on the tissues and
see how that person’s body responds (Nam et al., 2015). This alone is an incredible tool because
prior to these engineered models the only way to test a medication or treatment type on a specific
patient was to have them undergo the treatment or take the medication and observe the results.
With this ability, the process of finding a tailored treatment for an individual is faster, as well as
less invasive to their body.
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History of Tissue Engineering
The term “tissue engineering” has been used since the implementation of the National
Organ Transplant Act back in 1984. However, even before this term was birthed, there were
ancient Hindu myths that tell of clones being produced from a person’s blood (Kaul & Ventikos,
2015). Furthermore, in Greek mythology, there is a legend about Prometheus who committed
treason and was sentenced to an eternity of his liver being pecked out by an eagle and
regenerating itself every time (Kaul & Ventikos, 2015). These are just a few of the examples of
myths or tales that contain ideas of a part of a person’s body having the ability to regenerate. In
ancient times, regenerative medicine was not established, but there are records indicating that a
form of it was used (Kaul & Ventikos, 2015). For example, a recovered Egyptian papyrus
contained instructions for regenerating new tissue from wounds by a “scaffold” method. These
scaffolds included the use of herbs and organic material, but the idea is still the same. They
desired to make a prototypic environment that would cause new cells to proliferate and create
new tissue (Kaul & Ventikos, 2015). Regenerative medicine and its associated treatments have
developed over the years to produce the methods that are in place today.
During the second half of the nineteenth century, a man named Rudolf Virchow (as cited
in Kaul & Ventikos, 2015) stated that tissue regeneration was dependent on cell proliferation,
which led to the testing and experimenting of exponentially growing cells ex vivo. This
proposition was made after another scientist discovered that the regeneration of tissues depended
on the types of cells and the environment in which the tissue was surrounded. The studies
performed to proliferate cells outside of the body led to the coining of the term “stem cells”,
which were discovered through this process (Kaul & Ventikos, 2015). In the beginning of the
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twentieth century, roughly 30 years after stem cells were discovered, cell growth was finally
achieved ex vivo (Kaul & Ventikos, 2015). Alexis Carrel, the scientist who received the Nobel
prize in 1912, developed a method for proliferating cells in large quantities. This technique is
known as cell culturing, and is used even today (Kaul & Ventikos, 2015). Through his
experiments, Carrel also discovered that pieces of an animal’s heart, when placed in plasma and
embryonic tissue, were able to not only survive, but also continue to grow for an extensive
period of time. This was a huge breakthrough and accomplishment for tissue engineering
because this supported the hypothesis that a cell is closely dependent on its microenvironment
for new tissue growth (Kaul & Ventikos, 2015).
Upon the discovery of the stem cell, scientists quickly began using these types of cells for
regenerative medicine due to their ability to adapt and regenerate or repair the old, damaged
tissue (Ramsay, 2002). These types of experiments did not progress or gain footing until the late
twentieth century. However, once they started, the concept quickly gained momentum with the
incredible hope anticipated for the future of medicine (Kaul & Ventikos, 2015). Researchers
conducted experiments to find methods through which they could add these growth instructions
inside the body for the implanted cells to follow directions leading to new growth. This led to the
discovery of the main foundation for tissue engineering through the creation of a biosynthetic
matrix, ultimately leading to the design of scaffolds (Kaul & Ventikos, 2015). With this
development, researchers now had a firm basis on which to build their experiments and finally
produce tissue and, eventually, organs.
One of the first successful attempts involving tissue engineering was by a man named
Howard Green (Nam et al., 2015). He was able to reconstruct the epidermis from his patients’
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biopsies by extracting the cells of the epidermis, specifically keratinocytes, and causing them to
multiply rapidly (Nam et al., 2015). This was the first success of many that increased the
momentum and excitement for tissue engineering. Eventually, tissues were being produced
through the synthesis of scaffolds and extracellular matrix prototypes that were able to replicate
the tissue when implanted and combined with the cells (Vacanti, 2006). The very first human
implant from engineered tissue was in 1991 (Vacanti, 2006). The engineered implant contained a
scaffold that was synthetically produced and seeded with chondrocytes. The patient had Poland
Syndrome where his chest was not developed, and he lacked a sternum. The purpose was to see
if the engineered scaffolding would cause new growth to occur inside the patient’s body
(Vacanti, 2006). The procedure was successful, and the synthesized scaffolding integrated into
the patient’s body and the results were better than expected. As time progressed, similar
procedures occurred across the world which supported the idea that this new regenerative
medicine could be successfully implemented for the replacement of human parts (Vacanti, 2006).
Over the years many technological advances occurred leading to the production of whole organs,
which is the basis and purpose for tissue engineering.
Components of Tissue Engineering
With a basic understanding and knowledge of the background of tissue engineering, it is
important to define the parts that allow tissue engineering to exist in further depth. To begin,
there are roughly three components that allow tissue engineering to exist and succeed: the
scaffolding, the cells and the molecules. Without any one of these elements, the process of tissue
engineering cannot work.
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Scaffolds
The scaffolds act as a template or environment for the regeneration of the tissue
(O’Brien, 2011). These constructions are incredibly important for the proliferation of the cells.
They are intricately composed of fabricated biomaterials with key requirements that must be
followed when synthesizing them (O’Brien, 2011). The first factor is that they must be
biocompatible. This refers to the scaffold’s ability to proliferate the cells and cause them to
adhere to the structure, even prior to being placed inside the body. It also must not induce an
immune response that leads to inflammation. If this occurs, then the healing process will be
prolonged and will often lead to a rejection of the scaffolding and new material by the body.
Secondly, the material that the scaffold is composed of must be biodegrable, so that once
placed inside the body it will provide structure but ultimately be broken down. The entire
purpose of tissue engineering is to cause an individual’s cells to regenerate their own
extracellular matrix to heal their body with the cells that are already inside them. However, they
need a blueprint in order to start the process of engineering the matrix, which is where the
scaffolding comes in play. Once implanted inside the body, the cells will continue following the
instructions of the scaffold but over time produce the matrix on their own. Since the scaffolding
is not needed long term, it is important to compose it of materials that are able to be degraded
and removed from the body without any problems or negative effects.
Another key factor is that the scaffolding must be porous to allow the diffusion of
elements and nutrients throughout the structure, as well as allow the cells to penetrate it for
further proliferation. A difficulty that has been observed with this component is that the pores of
the scaffold must be big enough to allow the cells to enter the structure in order to bind with the
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ligands inside. Simultaneously, they must maintain a large enough surface area for cells to bind
on the outside in greater numbers. This is critical for the integration of the cells with the scaffold,
because this is the method by which the cells cause regeneration of the tissue.
Lastly, the most important requirement to consider when constructing the scaffolds is the
material with which to develop them. There are three categories of biomaterial used for
constructing scaffolds: synthetic polymers, ceramics and natural polymers (O’Brien, 2011). Each
of these groups have their own advantages and disadvantages. The choice of which biomaterial
to use often depends on the type of tissue that is being regenerated inside the body. For example,
ceramic scaffolding is frequently seen in the engineering of new bone growth, because the
material is characterized by its low elasticity, brittle surface and stiffness. These features are
ideal for bone regeneration due to their similarity in structure. However, there are downsides to
using this material. Many of the issues stem from the brittleness and the inability to mold or
shape the material and the newly engineered tissue.
The most promising biomaterials are the natural polymers due to their ability to promote
growth, adhesion and proliferation of the cells. The natural polymers also have the best response
for degradation because there are no fatal byproducts produced with their breakdown. This
allows the cells to create their own extracellular matrix with time due to the ability to degrade the
destructive residual material. The issue presented with natural polymers is that their mechanical
properties limit their ability to be used as biomaterial for certain tissues that need to have a
weight-bearing ability, specifically with application to orthopedics (O’Brien, 2011).
Furthermore, the vasculature of the scaffolds is a major challenge and is one of the areas in need
of further research. There is still substantial investigation that needs to be done to produce the
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most efficient, functional scaffold. However, there has been major success with the methodology
of these structures and even an ability to integrate them into clinical trials.
There are two main approaches in which researchers are engineering tissue (Howard et
al., 2008). The first is where the scaffolding can be used as a cell support system. The cells are
seeded outside of their normal conditions and directed to begin the process of creating the
materials needed for tissues. These genetically engineered cells are the starting material for the
rest of the tissue. The second approach is where the scaffolding is used as a growth factor for the
implanted cells so that new cells can be drawn to the site and create new growth. The cells that
are most successful in tissue engineering are primary cells which are taken directly from the
patient. Researchers hope that they will be able to combine growth factors with stem cells to
allow the tissue and cells to regenerate and cause new growth. Researchers have also tested and
found that biomaterial scaffolding is more than just structural support in constructing tissues. It is
a way to integrate new modified tissue and cells into the body where new growth needs to occur.
They have tested and are continuing to test the different methods of using biomaterial to
reconstruct cells. Researchers are beginning to genetically manufacture new tissue with the
extracellular matrix by creating biopolymers, proteins, and smart polymers. With the next stage
of tissue engineering, researchers are hoping to discover more bioactive materials that will be
useful for future endeavors (Furth et al., 2007).
An emerging approach for tissue engineering that has had an increase in its development
relates to the reconstruction of damaged osteochondral interface, or the cartilage-bone interface.
The osteochondral interface is a difficult area for engineering new tissue because the tissue of
both the cartilage and the bone are very different and need separate, specific composition.
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However, several types of scaffolding have been developed that will hopefully aid in growth and
regeneration for both sides of attachment. There are four proposed scaffolds being tested by
researchers within the osteochondral interface to see which option has the greatest success rate.
The make-up of the scaffold is incredibly important because there are many qualities it must
possess. One of the main limitations when developing cartilage tissue is that it has a low selfregenerating power. For osteochondral regenerative tissue, it must have actively proliferating
cells, and so many have suggested and incorporated the use of mesenchymal stem cells (Nooeaid
et al., 2012).
Cells
The next key components in the process of tissue engineering relates to the cells that
form extracellular matrix. Prior to researchers developing the idea of engineering whole organs,
guided tissue regeneration existed (Sakaguchi et al., 2019). The procedure consists of an
injection of cells from the patient into the site of injury. The process causes the desired cells to
proliferate in the area, which creates a barrier preventing the unwanted cells from growing and
developing. Once scaffolds were introduced, the methodology for engineering tissues changed.
The cells now had an easier process for proliferating and producing an extracellular matrix for
new tissue growth because scaffolds provide a surface area and contain a porous membrane.
These components allow the integration and adhesion of the cells leading to their rapid increase
in numbers. Initially, the scaffolds are seeded in vitro, where cells are spread on the structure and
encouraged to adhere and grow. This process is performed on a media with nutrients and growth
factors which are necessary for the growth and establishment of the tissue (Sakaguchi et al.,
2019).
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The cells being used for tissue engineering come from the patient or individual in need of
new tissue. The reason that the cells are collected from the individual is because when the new
tissue is engineered and able to be integrated back into their body, there is a significantly lower
risk of producing an immune response. As discussed earlier with organ transplants, the patient
must first receive immunosuppressant medications in order to repress their immune system so it
will not reject the new organ being integrated into their body. The beauty of tissue engineering is
that since the person’s own cells are producing the matrix and ultimately the tissues, the body
should not reject its own cells. The cells being used for this technique are stem cells from the
patient, often adult stem or hematopoietic cells (Olson et al., 2011). These cells can be extracted
from the bone marrow, adipose, skeletal muscle and gastrointestinal tract. Other stem cells that
have been looked at for research include embryonic stem cells (Ramsay, 2002). They are found
in a blastocyst, in the inner mass of the cell, specifically in humans. However, there is much
debate in the science realm regarding the ethicality of this matter because upon extraction of the
embryonic stem cells, the blastocyst is eradicated.
Cell culturing is important for tissue engineering because the cells must expand in
numbers and grow exponentially in a lab prior to integration in the body. Normal cell culturing is
different compared to culturing with 3-D scaffolds (Sakaguchi et al., 2019). It is important for
the seeding of the scaffold to be done quickly and efficiently, ensuring that all areas of the
scaffold are equally distributed with the cells because a uniform tissue is the desired outcome.
The integration of the cells to the scaffold in the lab is a key component in the process of seeding
because it ensures the reproduction of functional tissue that will continue to develop once inside
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the body. Along with seeding, it is important to use growth factors that result in even,
exponential growth across the structure.
Stem Cells. The discovery of stem cells was an incredible accomplishment for the world
of medicine. They have become one of the leading reasons for the development of tissue
engineering and regenerative medicine (Gomillion & Burg, 2006). Stem cells have
revolutionized regenerative medicine because they are cells that they have not differentiated into
a specific type or subset of cells in the body (Bianco & Robey, 2001). They also have incredible
ability to expand and proliferate rapidly. The fact that these cells are not specialized makes them
incredibly beneficial for use in tissue engineering. They have the ability to self-renew and can be
used in any area of the body, specifically in sites needing repair. Stem cells, after migration to
the sites of need, are able to produce progeny cells that are capable of forming different tissue
types in the body (Sakaguchi et al., 2019). With the appropriate signals, stem cells can
differentiate into mature cells with specializations for specific regions and tissues. These cells
also possess the ability to propagate in a lab, which is important for proliferation in vitro with the
scaffolds. There are several different types of stem cells but the one that has proven most
efficient and productive are the mesenchymal stem cells.
Mesenchymal stem cells are superior materials to use in tissue engineering. They are
found in the bone marrow of adults and exist as one of the subsets of multipotent stem cells.
Multipotent are the more restrictive stem cells as they can only produce daughter cells that are
specific to a couple types of tissues (Rosenbaum et al., 2008). However, these specific stem cells
are used frequently due to their ease of isolation (Rosenbaum et al., 2008). They are complex
cells that can split into different mesenchymal types, such as ones that can be used to make
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specific bone marrow tissue. These cells have greatly helped tissue engineers because they are
capable of being used in cartilage, bone, tendons, and ligaments, as well as other connective
tissue. Furthermore, mesenchymal cells are constantly being produced and proliferating while
others are simultaneously dying due to their lifespan. This is an important aspect because the
cells that make up tissues progress rapidly with time and need new cells to be produced. For new
tissue engineering, researchers are creating a modified cell and replacing these fresh, new cells
with the dying ones during the turnover cycle. They have used the mesenchymal cells and
transferred them to locations that need repairs such as injuries or other tissue-damaged sites
(Caplan, 2007). While these stem cells are not as versatile as embryonic stem cells, researchers
have preferred to use them because they are successful with tissue engineering and they are not
having to face a moral and ethical dilemma.
Growth Factors
The last key component to the success of tissue engineering is the use of growth factors
and cytokines. Growth factors are specific proteins that promote growth and proliferation of
tissues or cells (Chen et al., 2010). Furthermore, they have the ability to send signals and
maintain communication between cells and the extracellular matrix. They are important in the
process of cell differentiation and tissue repair, which is why they are necessary for the
engineering of tissues. Pertaining to wound healing, growth factors direct and act as instructions
for the regrowth of new tissue through repair. They work through pathways and trigger the
signaling of many of them. Because growth factors are important to signaling pathways, the
number of receptors dictates how responsive the cell is, as well as how it responds (Chen et al.,
2010). Cell proliferation is based on numerous factors, most of them involving the environment
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and nutrients. However, growth factors are among the key ingredients needed for proper
expansion. The goal for tissue regeneration is to mimic the environment of the body specifically
with the development of tissues and cells (Chen et al., 2010). Thus, it is important for the
integration of growth factors to replicate that ideal, imitated environment. One of the ways in
which tissue engineering has approached reproduction is by creating a replica of the cascade of
wound healing (Chen et al., 2010). This cascade cannot occur without the help of growth factors
to ensure proper development of new healthy tissue to replace the old, damaged parts. They
stimulate the body to repair the site of the injury, signaling for the correct cytokines and cells to
migrate to the location and perform their functions. In order for the growth factors to function
properly, they must be able to travel to the site of injury prior to degradation and upon reaching
the location, live long enough to complete their course of action (Chen et al., 2010). This
functions properly inside the body, but when translocated to laboratory settings, the approach is a
bit different. Researchers have concluded that they must enable other signaling molecules to help
initiate the signaling cascade for wound healing in order to properly ensure the correct responses
(Chen et al., 2010). The techniques for delivery of the growth factors to the cells and scaffolding
is an area that needs further research to discover the best option. The key growth factor families
that have been found to effectively aid and function properly with tissue engineering have been
the transforming growth factor – beta, hepatocyte growth factor, connective tissue growth factor,
and several more families.
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Final Process of Tissue Engineering
The process of engineering the actual tissue is an intense process. To begin, the
scaffolding must first be developed (Godbey & Atala, 2002). The detailed production starts with
the choosing of the biomaterial to use as the basis of the structure. Once the scaffold is put
together, the cells must then be extracted, whether from the patient or another source. The cells
are then seeded onto the scaffold, and the entire 3-D model is incubated in specific mediums that
contain nutrients and growth factors. This process allows the cells to adhere to the scaffolding
and proliferate across the surface, creating the extracellular matrix, which forms the tissue. After
this has occurred outside the body, the entire model can then be integrated into the body at the
desired location. The scaffold will eventually be degraded down and eliminated from the body,
leaving the cells to continue to regenerate the new tissue. Researchers have been able to produce
full organs through the same process as previously described.
Conclusion
Tissue engineering is an emerging field of treatment in medicine. It provides many
patients with wounds, injuries, and scar tissue to heal faster and more efficiently. It is a type of
regenerative medicine that is promising in many aspects, including future treatments like
surgeries and transplants. There has been an incredible amount of success that has sprung from
this form of medicine; however, there is still significant research and testing that must transpire
before it gets to the desired goal. The future for tissue engineering is very promising as it will
eventually remove the need for a transplant list, which will be an amazing feat for the world of
medicine and mankind. There are still many questions needing to be answered such as long-term
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effects and potential problems with this technique, but advancements in technology and research
will provide the basis for the future of tissue engineering.
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